Furthermore, we found beneficial-cluster of specific methylation markers (PCDH20, APCDD1, COCH) that could be used in conjunction with microsatellite status to expand the pool of colon cancer patients eligible for immunotherapy. This evidence concerns the gene COCH and malignant colon neoplasm.